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IDENTIFICATION OF AUTOANTIBODIES TO THE I PROTEIN OF THE 
HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN COMPLEX IN 
PATIENTS WITH SYSTEMIC SCLEROSIS 
CAFCOMAURIZIO MONTECUCCO, ROBERTO CAPORALI, 
F B I 0  COBIANCHI, and GIUSEPPE BLAMONTI 
Objective. To assess the presence of autoantibod- 
ies to the I protein (polypyrimidine-tract binding pro- 
tein) of the heterogeneous nuclear RNPs (hnRNP) in 
different connective tissue diseases. Antibodies to other 
hnRNP proteins (Al, A2, and B) have been previously 
found in patients with rheumatoid arthritis (RA), sys- 
temic lupus erythematosus (SLE), and mixed connective 
tissue disease (MCTD). 
Methods. Sera from 101 patients with various 
connective tissue diseases and 25 normal controls were 
investigated by enzyme-linked immunosorbent assay 
and immunoblotting, for their reactivity to highly puri- 
fied recombinant hnRNP I. Moreover, reactivity to 
cellular hnRNP I protein was investigated by immuno- 
blotting using a partially purified preparation of 
hnRNP proteins (including Al ,  A2, B, and I), and by 
indirect immunofluorescence. For the analysis of the 
fluorescence pattern, affinity-purified antibodies to 
hnRNP I, obtained from a selected patient, were tested 
on HEp-2 cells. 
Results. By immunoblotting, antibodies reacting 
to recombinant hnRNP I were found in 22 of 40 patients 
with systemic sclerosis (SSc), 3 of 32 with RA, 0 of 23 
with SLE, and 0 of 6 with MCTD. Antibodies to re- 
combinant hnRNP I were more frequently found in 
patients with pre-SSc or limited SSc (15 of 24) than in 
those with intermediate or diffuse SSc (7 of 16). In 
indirect immunofluorescence studies, affinity-purified 
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anti-hnRNP I autoantibodies gave a diffuse nucleoplas- 
mic staining. Using an hnRNP preparation from nu- 
clear extracts, anti-hnRNP I reactivity was detectable in 
SSc sera, while it was not detectable in RA, SLE, and 
MCTD sera reacting with hnRNP NB proteins. 
Conclusion. Human autoimmune sera show dis- 
tinct patterns of anti-hnRNP reactivity, i.e., anti-A/B in 
SLE and RA sera, and anti-I in SSc sera. This suggests 
that A/B proteins and the I protein may be involved in 
different dynamic hnRNP complexes that elicit different 
autoimmune responses. From a clinical perspective, 
anti-hnRNP I antibodies are frequently associated with 
pre-SSc features, suggesting an early appearance of 
these antibodies during the course of the disease. 
RNA (messenger, heterogeneous nuclear, small 
nuclear, and ribosomal) exist within the cell in associa- 
tion with specific proteins to form RNP complexes 
(mRNP, hnRNP, snRNP, and ribosomes). It is com- 
monly accepted that the protein component of these 
complexes is essential to modulate different aspects 
characterizing the life of the cognate RNA, such as 
maturation, stability, and function (1). In the last 2 
decades a growing number of autoantibodies to RNA- 
associated proteins have been identified in connective 
tissue diseases. Most of the described autoantibodies are 
directed to proteins belonging to the snRNP complexes 
or to ribosomes. These autoantibodies represent valu- 
able tools for the diagnosis and prognosis of auto- 
immune rheumatic diseases (2-4). 
However, very few studies have addressed the 
existence of autoantibodies directed to proteins of the 
mRNP and hnRNP complexes, in spite of their relative 
abundance and key role in the posttranscriptional con- 
trol of the mRNA and pre-mRNA fate. This scarcity of 
data probably derives from the technical difficulties in 
purifying well-defined protein-hnRNA or -mRNA com- 
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plexes. For the same reason, only recently has the 
structure and function of these complexes begun to be 
analyzed, particularly with regard to the hnRNP parti- 
cles (1,5). 
About 20 major hnRNP proteins have been iden- 
tified in mammalian cells as bona fide hnRNP proteins, 
and they have been given designations ranging from A1 
(34 kd) to U (120 kd) (1). The complementary DNA 
(cDNA) for most of them have been isolated and 
sequenced. Some of these proteins (hnRNPs A, B, and 
C) belong to the family of proteins containing the 
so-called RNA binding domain. Others (hnRNPs I and 
L) are characterized by protein motifs somewhat related 
to the RNA binding domain (6) .  The remaining hnRNP 
proteins possess unique sequence features. In any case, 
the definition of the protein component of the hnRNP 
complexes, the development of biochemical procedures 
suitable for their purification, and the expression of 
single-protein species in prokaryotic systems have made 
it possible to investigate the presence of autoantibodies 
that are directed toward the hnRNP proteins, although 
it is not yet possible to analyze their presence in intact 
hnRNP complexes. 
Antibodies to the hnRNP proteins, first reported 
by Fritzler et a1 (7), have been detected and character- 
ized in several studies of systemic lupus erythematosus 
(SLE), mixed connective tissue disease (MCTD), and 
rheumatoid arthritis (RA) (8-12). In all of these studies, 
only the reactivity toward the hnRNP A/B proteins was 
analyzed. These proteins (Al, A2, B1, and B2) are highly 
similar in sequence and are therefore immunologically 
related (1). 
Herein we report the first evidence of human 
autoantibodies directed to the hnRNP I, a 60-kd protein 
that has been proven to be the same as the recently 
described polypyrimidine-tract binding protein (13). The 
hnRNP I protein has some distinct features: 1) it binds 
hnRNA preferentially to the polypyrirnidine tract near 
the 3’ end of introns, but lacks the canonical consensus 
sequences of the RNA binding domains found in 
hnRNPs A, B, and C as well as in several snRNP 
proteins; and 2) it seems to localize diffusely in nucleo- 
plasm, similar to other hnRNP proteins, but is also 
concentrated in an as-yet-unidentified perinucleolar 
structure (1,6). 
Autoantibodies reacting with hnRNP I are 
present in sera from patients with various connective 
tissue hseases. However, their occurrence is different 
from that of anti-hnRNP A/B because anti-hnRNP I 
are associated with the clinical features of systemic 
sclerosis (SSc). 
PATENTS AND METHODS 
Patients. This study was carried out using sera from 
101 patients with autoimmune connective tissue diseases and 
25 healthy control subjects. For each disease group, all sera 
collected during the 3 months preceding this study were 
included. Sera were collected for routine diagnostic proce- 
dures, i.e., tests for antinuclear antibodies on HEp-2 cells and 
for antibodies to extractable antigens by counterimmunoelectro- 
phoresis, and were then stored at -80°C. A complete clinical 
history was obtained for each patient by retrospective chart 
review. 
Twenty-nine patients who had SSc fulfilled the Amer- 
ican College of Rheumatology (ACR; formerly, the American 
Rheumatism Association) preliminary criteria for the classifi- 
cation of SSc (14) and were grouped in different clinical 
subsets according to the extent of skin involvement, i.e., limited 
SSc, intermediate SSc, or diffuse SSc (15). Eleven additional 
patients had Raynaud’s phenomenon, defined as cold-induced 
blanching and cyanosis of the fingers, and had either anticen- 
tromere antibodies or scleroderma-like nailfold capillary ab- 
normalities (16) or both. These patients did not fulfill the ACR 
criteria for SSc, but were regarded as having a limited SSc or 
a pre-SSc condition, as previously described (17-20). In the 
present study, these patients were classified as having pre-SSc; 
most of them had cutaneous teleangectasias and/or esophageal 
dysmotility, and 2 had primary pulmonary hypertension. Six 
other patients had Raynaud’s phenomenon and fulfilled the 
criteria for MCTD proposed by Alarcon-Segovia and Cardiel 
(22). Finally, 32 patients had RA and 23 had SLE according to 
the ACR criteria (23,24). 
Expression and purification of the recombinant anti- 
gen, Polymerase chain reaction was used to tailor the hnRNP 
I cDNA for expression in Eschen’chia coli, using the expression 
system pRC23 (25). The human hnRNP I cDNA (kindly 
provided by C. Morandi [6]) was amplified with N-terminal 
and C-terminal(5’-AATCAAGCITATGbpAAGTCGTCGC- 
AGGGGG-3’) oligonucleotides. The amplified product was 
digested with Eco RI and Hind I11 and subcloned into the 
corresponding sites of pRC23. After E cofi transformation 
(25), the sequence of the recombinant plasmid was verified by 
the dideoxy-chain termination method (Sequenase kit; United 
States Biochemical, Cleveland, OH). 
Cell growth and induction of the protein were per- 
formed as previously described (26). The washed frozen cells 
from a 2-liter culture were resuspended in 30 ml of buffer A 
(20 mM HEPES, 0 . M  KCl, 0.2 mM EDTA, 0.5 mM dithio- 
threitol, 0.4 mM phenylmethylsulfonyl fluoride, pH 7.9) and 
lysed by sonication. The suspension was centrifuged at 20,OOOg 
for 20 minutes at 4°C and the supernatant fraction was loaded 
on a 50-ml DEAE-cellulose column (2.5 X 10 cm) connected 
in tandem with a 5-ml agarose-poly U column (AGPOLY U 
type 6, 1.0 X 6.5 cm; Pharmacia, Brussels, Belgium). Both 
columns were equilibrated and run with buffer A. 
The DEAE column was disconnected and the agarose- 
poly U column was then washed with 25 ml of buffer A. After 
subsequent washing with 25 ml each of buffer A containing 
either 200,300,500, or 750 mM KCI, hnRNP I was eluted from 
the column with 15 ml of buffer A containing 1M KCl. The 
eluate was concentrated by ultrafiltration (Centricon-10; Ami- 
con, Beverly, CA) as described by the manufacturer. 
(5’-AGAATGAATTCCATGGACGGCATTGTCCCA-3’) 
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Figure 1. Agarose-poly U chromatography. The material passing through the DEAE-cellulose column (L) interacted with the 
agarose-poly U column, and heterogeneous nuclear RNP I (hnRNP I) protein bound quantitatively to the column. The flowthrough 
fraction of agarose-poly U column (F.T.) corresponds to 100 mM KCI, and bound proteins were eluted with KCI as indicated. The 
samples were run on a 12.5% polyacrylamide gel and dye stained with Coomassie blue. Molecular masses in kilodaltons are given on 
the left 
Purification of hnRNP proteins from nuclear extracts. 
The hnRNP proteins were purified from 5 gm of exponentially 
grown HeLa cells, according to the method described by 
Pinol-Roma et a1 (27). The purified hnRNP proteins were 
stored at -80°C in 50% glycerol. Sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE), transfer to 
nitrocellulose, and immunologic detection with antibodies 
were performed as previously described (28), except that all 
incubations were done in 5% skim milk (Difco, Detroit, MI). 
All the sera tested were used at a 1:100 dilution and revealed 
with peroxidase-conjugated rabbit antibodies to human IgG 
(Dako, Milan, Italy). 
A rabbit antiserum directed against a subset of bovine 
hnRNP proteins was used as the positive control. This rabbit 
antiserum was specific for hnRNPs Al,  A2, B1, B2, and I, as 
previously described (6,29). Anti-hnRNP antibody concentra- 
tion in rabbit serum is very high, and binding to purified 
recombinant hnRNP I was still detectable by enzyme-linked 
immunosorbent assay (ELISA) at a final dilution of 1:100,000. 
Immunoblots and ELISA One microgram of recom- 
binant hnRNP I was mixed in 62.5 mM Tris HCI, pH 6.8, 
containing 5% 2-mercaptoethanol, 2% SDS, and 0.1% brom- 
phenol blue, heated at 100°C for 5 minutes, and then centri- 
fuged. The supernatant was loaded on a 10% SDS-PAGE 
column and run at 30 mA for 4 hours. The gel was blotted onto 
a nitrocellulose sheet that was cut into strips, washed, and 
processed as previously described (28). Human sera were 
tested at a 1500 dilution, and peroxidase-conjugated antibod- 
ies to human IgG were used as a secondary probe. 
Patient sera, reacting with recombinant hnRNP I, were 
also studied by ELISA at 1:100 and 1:1,OOO dilution. ELISA 
was performed in triplicate, as previously described, for recom- 
binant A1 protein (11) using peroxidase-conjugated antibodies 
to human IgG (Dako). The optical density (OD) was measured 
at 492 nm using a Titertek multiscan reader (Flow, Opera, 
Italy). The cut-off value was established as 3 SD above the 
mean for normal controls (8 controls for each 96-well plate). 
Arbitrary units were obtained according to the formula patient 
OD value/cut-off value. To rule out nonspecific binding, all 
sera were also tested on uncoated wells. 
Affinity purification of anti-hnRNP I antibodies and 
indirect immunofluorescence. Affinity purification of anti- 
hnRNP I antibodies was performed essentially as previously 
described (30). Briefly, 200 pg of purified recombinant hnRNP 
I protein was loaded onto the entire length of a 10% SDS- 
PAGE. After the gel had been run, proteins were transferred 
to a nitrocellulose filter and stained with Ponceau. A nitrocel- 
lulose strip corresponding to the hnRNP I was cut, incubated 
for 30 minutes in blocking buffer composed of Tris buffered 
saline (TBS; 10 mM Tris HCI, pH 7.4,0.9% NaCI) rendered in 
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Figure 2. Reactivity of anti-hnRNP rabbit antibodies and human 
systemic sclerosis (SSc) sera (1:500 dilution) to recombinant hnRNP I 
protein. Four different human pre-SSc and SSc sera (lanes 1-4), 1 
normal human serum (lane C), and rabbit antibodies (1:10,000) (lane 
R) were utilized in immunoblots to stain 1 pg of recombinant hnRNP 
I protein. For comparison, staining of total cell extracts (10 mg of wet 
cell pellets) from HeLa cells (lane H) and NT2/D1 teratocarcinoma 
cells (lane T) with the same rabbit antibodies is shown. The position of 
the cellular hnRNP I protein is indicated on the left. The doublet 
detectable in lanes R-4 corresponds to hnRNP I and its major 
degradation product, which originated during purification. In contrast, 
the 2 bands present in total cell extract (lanes H and T) probably 
represent hnRNP I isoforms (see ref. 6). Molecular masses in kilodal- 
tons are given on the right. See Figure 1 for other definitions. 
2% skim milk, and then incubated overnight at 4°C with 300 p1 
of patient serum at 1:4 dilution with gentle shaking in an 
Eppendorf tube. 
The serum remaining after this incubation showed no 
recognition of hnRNP I either in the ELISA or in the 
immunoblotting studies. This serum was kept for further 
immunofluorescence analysis (depleted serum). After rinsing 
the filter twice in TBS, the antibodies were eluted in 500 pl of 
elution buffer ( 0 2 4  glycine, pH 2.8, 1 mM EGTA) and 
immediately neutralized by adding 50 pl of lM Tris base. As 
expected, affinity-purified antibodies showed a strong reactiv- 
ity for hnRNP I by immunoblotting. 
Indirect immunofluorescence was carried out, as de- 
scribed (31), on methanol-fied HEp-2 cells, using total se- 
rum and anti-hnRNP I-depleted serum at 1:20 dilution, and 
on affinity-purified antibodies, as obtained by the above- 
described procedure, without further dilution. Fluorescein 
isothiocyanate-conjugated rabbit anti-human IgG antibodies 
(Dakopatts, Copenhagen, Denmark) were used as a secondary 
antibody. 
RESULTS 
Expression and purification of hnRNP I. The 
cDNA for the human hnRNP protein I has been isolated 
recently by immunologic screening of a human liver 
cDNA library (6). In order to extend the characteriza- 
tion of autoantibodies directed to proteins of the hnRNP 
complexes, we induced expression of hnRNP protein I in 
E coli. Recombinant protein was purified to homogene- 
ity by column chromatography using DEAE-cellulose 
and agarose-poly U matrices. Since most of the protein 
I (>90%) eluted in the flowthrough, and in the washes 
(100 mM KCl) of, DEAE-cellulose (results not shown), 
a simple purification scheme was adopted in which, in 
order to speed up the process of purification, the 
DEAE-cellulose column was connected in tandem with 
the agarose-poly U column. This matrix was chosen on 
the basis of the reported binding preference of protein I 
to poly U iibopolymers (29). As shown in Figure 1 
(intentionally overloaded), the protein eluted, after ex- 
tensive washes, at 1M KCl as a homogeneous protein. 
The purified recombinant hnRNP I protein had 
an apparent molecular mass of 60 kd, as shown in Figure 
1. After concentration and upon storage, it resolved into 
a doublet of bands, both of which were recognized by the 
rabbit antiserum utilized to isolate the cDNA (Figure 2). 
The band with a slightly lower molecular mass repre- 
sents a proteolytic product that originated during the 
purification procedure. 
Reactivity to recombinant hnRNP I. Human sera 
were tested against purified recombinant hnRNP I by 
both ELISA and immunoblotting. A screening test was 
carried out by means of ELISA with a 1: lOO dilution of 
the sera. Sera from 25 normal controls and 101 patients 
(40 with SSc, 32 with RA, 23 with SLE, and 6 with 
MCTD) were tested. Higher than normal serum values 
for hnRNP I reactivity were found in nearly 80% of SSc 
patients, 20% of RA patients, and 20% of SLE patients, 
as well as in 2 of 6 MCTD patients (Figure 3). Using a 
1:1,000 dilution of the sera, however, only 11 sera (all 
from SSc patients) gave positive values for hnRNP I 
reactivity. 
To exclude nonspecific binding, all sera were also 
tested on uncoated wells. No SSc serum, tested in this 
way, showed O D  values higher than the cut-off value. To 
rule out the possibility that the observed results could be 
due to a reactivity to bacterial contaminant proteins, 
albeit undetectable by SDS-PAGE analysis (see Figure 
l) ,  we used the human sera in immunoblot experiments. 
In these experiments, 1 pg of recombinant protein was 
used and probed with a 1500 dilution of the sera. No 
differences were observed in the staining of protein 
bands between these experiments and those using the 
purified recombinant protein, thus confirming the data 
obtained in the previous analysis. Some representative 
results are shown in Figure 2. A significant reactivity was 
found in 22 of 40 patients with either SSc or pre-SSc and 
in only 3 of 32 patients with RA. None of the 28 patients 
with SLE or MCTD showed detectable anti-hnRW I 
reactivity. No reactivity was ever observed with control 
sera at the dilution utilized. 
It is worth noting that all patient sera showing >2 
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arbitrary units in the screening test by ELISA were also 
positive for hnRNP I staining by immunoblotting (Fig- 
ure 3). Anti-hnRNP I antibodies, as detected by immuno- 
blotting, were present in all of the different SSc subsets 
(Table l), although they were more frequently found in 
patients with pre-SSc and limited SSc (15 of 24) than in 
those with either intermediate or diffuse SSc (7 of 16). 
No specific association was found with either anticen- 
tromere or anti-Scl-70/topoisomerase I or with any 
other clinical characteristics. 
Reactivity to hnRNP proteins purified from nu- 
clear extract. As shown previously, ll of the analyzed 
sera had antibodies to recombinant hnRNP protein I, 
detectable by both immunoblotting and ELISA at 
1:1,000 dilution. We then investigated whether the same 
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Figure 3. Binding of human sera from patients with different auto- 
immune diseases to purified recombinant hnRNP I protein, as deter- 
mined by enzyme-linked immunosorbent assay (screening test at a 
1:lOO dilution of the sera). Shaded area represents the range of optical 
density values lower than the cut-off value of 1 arbitrary unit (a.u.). 
The cut-off value was chosen as 3 SD above the mean for normal 
control optical density values. Open symbols in the systemic sclerosis 
(SSc) and rheumatoid arthritis (RA) disease subsets represent sera 
with antibodies to recombinant hnRNP I that were also detectable by 
immunoblotting. Horizontal bar in the SSc column represents the 
mean value. SLE = systemic lupus erythematosus; MCTD = mixed 
connective tissue disease. See Figure 1 for other definitions. 
Table 1. Occurrence of antibodies to recombinant heterogeneous 
nuclear RNP I (hnRNP I), as detected by immunoblotting, in the 
different systemic sclerosis (SSc) subsets* 
Anti-hnRNP+ Anti-hnRNP- 
Clinical feature n (n = 22) (n = 18) 
Pre-SSc 11 8 (73) 3 (27) 
Limited SSc 13 7 (54) 6 (46) 
Intermediate/diffuse 16 7 (44) 9 (56) 
Anticentromere 17 9 (53) 6 (47) 
5 (63) Ant i-Scl-70 8 3 (37) 
An ti-SS-A/Ro 2 2 (W 
Rheumatoid factor 13 7 (54) 6 (46) 
s s c  
0 
* Values are the number (%) of patients positive for each clinical 
feature. No reactivity for definite nuclear antigens, other than Scl-70, 
SS-A/Ro (by counterimmunoelectrophoresis), or centromere (by indi- 
rect immunofluorescence using HEp-2 cells), was found in the patients 
with SSc. Among all 40 patients with SSc, 55% were positive and 45% 
were negative for anti-hnRNP I. 
Toward this aim, hnRNP proteins were chromatograph- 
ically purified from HeLa cells. As shown in Figure 4 
(lane C), this method led to the isolation of a set of 
hnRNP proteins with molecular masses ranging from 34 
kd to 68 kd. The presence, in this preparation, of hnRNP 
proteins A/B and I was detected by immunostaining with 
rabbit antibodies specific for this set of polypeptides (the 
same antibodies utilized for the isolation of both Al- 
and I-specific cDNAs) (6,26) (Figure 4, lane A). Of note, 
protein I was underrepresented in our hnRNP prepara- 
tion; nevertheless, the high-positive sera (detectable by 
ELISA at a 1:1,000 dilution) were found to bind cellular 
hnRNP I in immunoblot assay. Neither control sera nor 
sera with low-positive values (detectable only by ELISA 
at a 1:lOO dilution) were found to react with hnRNP I. 
All tested RA, SLE, and MCTD sera showed no recog- 
nition of hnRNP I. However, as expected on the basis of 
previously reported data (1 l), several of these sera were 
found to recognize other hnRNP proteins, namely Al,  
A2, B1, and, probably, C. Control sera were consistently 
negative for all of the hnRNP proteins (Figure 4). 
Immunofluorescence studies. All 11 sera with 
high-titer anti-hnRNP I showed a positive immunoflu- 
orescence test result for antinuclear antibodies on 
HEp-2 cells. Three of these sera had diffuse nuclear 
fluorescence only, 5 had a centromeric pattern associ- 
ated with weak diffuse nucleoplasrnic staining, and 3 had 
nucleolar fluorescence associated with a diffuse nucleo- 
plasmic staining. Serum that showed the highest binding 
in ELISA was selected for affinity purification experi- 
ments. Reactivity of this serum to hnRNP I protein 
purified from HeLa cells is shown in lane 1 of Figure 4. 
Figure 5 shows the indirect immunofluorescence pat- 
terns obtained with total serum (Figure 5A), affinity- 
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Figure 4. Presence of antibodies against different hnRNP proteins in 
autoimmune sera. Lane C,  hnRNP proteins purified from HeLa cells, 
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophor- 
esis and stained with Coomassie blue. Lane A, Western blot analysis of 
hnRNP proteins with rabbit antibodies. Lanes 1-N, hnRNP proteins 
inmunostained with sera (1:lOO dilution) from different autoimmune 
patients (1 with pre-systemic sclerosis [SSc], 2 with SSc, 3 with 
rheumatoid arthritis, and 4 with systemic lupus erythematosus) or from 
a normal individual (N). The position of relevant hnRNP proteins is 
indicated on the left. Molecular weight markers are indicated on the 
right. The band at about 66 kd represents a nonspecific reaction, since 
normal serum also seems to react with it. The band of approximately 
62 kd, detectable in lanes 1 and 3, has not yet been identified, but on 
the basis of its molecular mass, we may speculate that it corresponds to 
hnRNP L or M (see ref. 1). See Figure 1 for other definitions. 
purified anti-hnRNP I antibodies (Figure 5B), and 
anti-hnRNP I-depleted serum (Figure 5C) on HEp-2 
cells. Depletion of anti-hnRNP I antibodies resulted in 
a selective disappearance (or intensity reduction) of the 
diffuse nuclear staining, without affecting centromeric 
fluorescence. In contrast, as expected, affinity-purified 
anti-hnRNP I antibodies showed a prevalent diffuse 
nucleoplasmic staining. 
DISCUSSION 
This study demonstrates the presence, in human 
sera, of autoantibodies to the hnRNP I protein, one of 
the abundant hnRNP proteins in human cells (1). Evi- 
dence for the presence of anti-hnRNP I in human sera 
is based on 1) reactivity to purified recombinant hnFWP 
I by both immunoblotting and ELISA, 2) specific immu- 
nostaining of protein I in h n R W  protein preparation 
from HeLa cells, 3) selective disappearance of a weak 
diffuse fluorescent nuclear staining after absorption on 
purified recombinant hnRNP I protein, and 4) diffuse 
nucleoplasmic staining with affinity-purified anti- 
hnRNP I antibodies from a selected positive serum. 
These findings extend the as-yet limited analysis 
of hnRNP-directed autoimmunity. In addition, our re- 
sults seem to open new perspectives on the study of 
diagnostic parameters for rheumatic diseases and on the 
study of the biologic functions of single hnRNP proteins. 
In this context, it is worth noting that almost all sera that 
strongly reacted with the A/B proteins did not recognize 
the I protein (Figure 4). Furthermore, anti-hnRNP I 
reactivity was mainly associated with features of SSc, 
whereas SLE, RA, and MCTD patient sera preferen- 
tially recognized A/B proteins. Accordingly, significant 
binding to hnRNP I was found in SSc sera, but not in 
SLE and RA sera, when the purified recombinant 
polypeptide was used as the antigen source in immuno- 
blotting studies. Differences in the frequency of positive 
sera observed between immunoblotting studies and 
ELSA seemed mainly due to the different serum dilu- 
tions used. 
Positive results for hnRNP I reactivity were ob- 
A B C 
Figure 5. Immunofluorescence staining of HEp-2 cells with the same hnRNP I-positive serum used in lane 1 of 
Figure 4. The fluorescence patterns obtained with whole serum (A), anti-hnRNP I affinity-purified antibodies 
(B), and anti-hnRNP I antibody-depleted serum (C) are shown. See Figure 1 for definitions. 
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tained in nearly 80% of SSc patients, 20% of SLE 
patients, and 20% of RA patients, using ELSA at a 
1: lOO dilution. At a higher dilution (1:1,000), 28% of SSc 
sera were found positive, while none of the 61 sera from 
patients with other autoimmune rheumatic diseases 
showed positive results. These data suggest that antibod- 
ies to hnRNP I can be detected in the majority of sera 
from patients with SSc, and that high-titer antibodies are 
almost specific for this condition, whereas SLE and RA 
sera mainly react with the A/B hnRNP proteins (9-12), 
suggesting a different pattern of anti-hnRNP reactivity. 
In particular, the entire set of basic hnRNP core proteins 
(A/B) seems to constitute a common target of the 
autoimmune response in RA and SLE patients (Figure 
4), as has been recently addressed (10). 
Complex structures are common targets of auto- 
immunity in connective tissue diseases, so that antibod- 
ies directed to different proteins of a unique complex 
can be found in a single patient and in patients with the 
same disease (2-4). The data presented herein reveal 
that hnRNP proteins A/B and I are distinct targets of 
different autoimmune responses. According to the 
antigen-driven origin of autoantibodies, one may specu- 
late that these proteins may be involved in different 
dynamic hnRNP complexes. This would not be surpris- 
ing, since hnRNP protein binding is not random with 
respect to RNA sequence, and each different hnRNA 
associates with a unique combination of hnRNP proteins 
(1). Furthermore, A/B proteins and the I protein are 
sharply different in their predicted structures and con- 
siderable evidence has accumulated to suggest different 
functions in pre-mRNA processing (1). 
Relevant details on the distinct features of 
hnRNP I have been previously described (6). The 
hnRNP I protein binds RNA structures that are partic- 
ularly exposed and is released from hnRNP complexes 
more readily than most other abundant proteins, which 
might explain, in part, the selective autoimmune re- 
sponse to hnRNP I. Moreover, immunofluorescence 
microscopy with monoclonal antibodies has localized 
hnRNP I to the nucleoplasm of interphase HeLa cells 
and has shown 1 (occasionally, 2) spots per nucleus, 
which are always closely apposed to a nucleolus. It seems 
likely that these regions with a higher concentration of 
hnRNP I represent sites of transcription of specific 
hnRNA species (6 ) .  This preferential perinucleolar lo- 
calization is intriguing, since nucleolar or nucleolus- 
related antigens are a specific target of autoimmutle 
response in patients with SSc and related disorders 
Another intriguing point is the relationship be- 
(32-34). 
tween hnRNPs and RNA polymerase, since some 
hnRNP proteins assemble on RNA polymerase I1 tran- 
scripts as soon as they are synthesized (1,35) and auto- 
antibodies to RNA polymerases occur specifically in SSc 
(36,37). We believe that studies on the association of 
anti-hnRNP I with different SSc-associated autoanti- 
bodies might provide new insights on co-localization and 
function of the hnRNP I protein. 
In our patients, anti-hnRNP I reactivity was 
associated with a fluorescence pattern characterized by 
diffuse nucleoplasmic staining. A similar diffuse staining 
was also observed with affinity-purified anti-hnRNP I 
antibodies from a selected positive patient serum. The 
lack of perinuclear spots in our immunofluorescence 
studies could be explained by the different experimental 
system used (1,6). 
Most autoantibodies found in SSc are known to 
mark off separate clinical subsets of the disease. For 
example, anti-Scl-70 (topoisomerase I) are usually as- 
sociated with diffuse SSc, anticentromere with limited 
SSc, and antifibrillarin and anti-PM-Scl with SSc/ 
polymyositis overlap disease (17,18,32,38,39). Anti- 
bodies to hnRNP I were present in all SSc subsets in our 
study, but were found more frequently in those patients 
with pre-SSc and limited SSc. The occurrence of these 
antibodies in patients with features of pre-SSc suggests 
an early appearance during the course of the disease, 
similar to that observed for anticentromere antibodies 
(17,19). No significant association between anti-hnRNP 
I and anticentromeric reactivity was found in our study. 
However, the present series was too small to drawn any 
definite conclusion. 
Further studies on larger series are needed to 
evaluate the relationship of these antibodies to hnRNP I 
with clinical and serologic features, as well as to assess 
the behavior of these antibodies during the course of the 
disease. In particular, it would be interesting to prospec- 
tively evaluate those patients with pre-SSc or with iso- 
lated Raynaud’s phenomenon to ascertain whether these 
antibodies would be predictive of an evolution to overt 
SSc. At present, this can only be suggested by the lack of 
correlation of these antibodies with Raynaud’s phenom- 
enon in other connective tissue disorders such as 
MCTD. 
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